Ulmsten U, Ekman G, Andersson K E
Am J Obstet Gynecol. 1985 Nov 15;153(6):619-22. doi: 10.1016/s0002-9378(85)80245-3.
The effects of terodiline were evaluated in 24 women with genuine motor urge incontinence: Twelve patients participated in a double-blind crossover study and 12 in a subsequent long-term study. All patients were investigated by simultaneous urethrocystometry before and after treatment. During the controlled study the subjects were treated with placebo or 37.5 mg of terodiline daily for two 3-week periods. The long-term study covered a period from 6 months to 3 years. A significantly higher increase in both bladder volume at urinary leakage (from 170 to 270 ml, p less than 0.001) and bladder capacity (from 320 to 390 ml, p less than 0.01) was registered after terodiline treatment compared to placebo. In the long-term study the effects on these parameters were still more pronounced with an increase in bladder volume at leakage (from 180 to 300 ml, p less than 0.001) and in bladder capacity (from 290 to 430 ml, p less than 0.0001). Subjective improvement with terodiline treatment was reported by all but two patients in the double-blind study and by all in the long-term study. Side effects such as dryness of the mouth were reported by four patients receiving terodiline in the double-blind study and by six in the long-term study. No patient discontinued the treatment. Terodiline seems to be a promising alternative for treatment of motor urge incontinence in women.
对24名真性运动性急迫性尿失禁女性患者评估了特罗地林的疗效：12名患者参与了双盲交叉研究，另外12名参与了后续的长期研究。所有患者在治疗前后均通过同步尿道膀胱测压法进行检查。在对照研究期间，受试者接受安慰剂或每天37.5毫克特罗地林治疗，为期两个3周疗程。长期研究涵盖6个月至3年的时间段。与安慰剂相比，特罗地林治疗后，漏尿时膀胱容量（从170毫升增至270毫升，p<0.001）和膀胱容量（从320毫升增至390毫升，p<0.01）均有显著更高的增加。在长期研究中，对这些参数的影响更为明显，漏尿时膀胱容量增加（从180毫升增至300毫升，p<0.001），膀胱容量增加（从290毫升增至430毫升，p<0.0001）。在双盲研究中，除两名患者外，所有患者均报告特罗地林治疗有主观改善，在长期研究中所有患者均有改善。在双盲研究中，4名接受特罗地林治疗的患者和长期研究中的6名患者报告有口干等副作用。没有患者中断治疗。特罗地林似乎是治疗女性运动性急迫性尿失禁的一种有前景的替代药物。
